{
  "id": "61f7cc0c882a024a1000002a",
  "type": "factoid",
  "question": "What is the target of Sutimlimab?",
  "ideal_answer": "Sutimlimab is a novel humanized monoclonal antibody directed against classical pathway complement factor C1s.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/29737533",
    "http://www.ncbi.nlm.nih.gov/pubmed/30635392",
    "http://www.ncbi.nlm.nih.gov/pubmed/33261023",
    "http://www.ncbi.nlm.nih.gov/pubmed/33512410",
    "http://www.ncbi.nlm.nih.gov/pubmed/34482398",
    "http://www.ncbi.nlm.nih.gov/pubmed/31114413",
    "http://www.ncbi.nlm.nih.gov/pubmed/30559259",
    "http://www.ncbi.nlm.nih.gov/pubmed/32176765",
    "http://www.ncbi.nlm.nih.gov/pubmed/31523413",
    "http://www.ncbi.nlm.nih.gov/pubmed/31229501",
    "http://www.ncbi.nlm.nih.gov/pubmed/33826820"
  ],
  "snippets": [
    {
      "text": "Beyond PNH, complement inhibition has also shown efficacy and safety in cold agglutinin disease (CAD), primarily with the C1s inhibitor of the classical complement pathway, sutimlimab, but also with pegcetacoplan.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/34482398",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " The complement C1s inhibitor sutimlimab is an emerging option in the second line and may also find its place in the first line in specific situations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33512410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathway.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33826820",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sutimlimab is a novel humanized monoclonal antibody directed against classical pathway complement factor C1s. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32176765",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Therapeutic options for these complement-mediated disorders are limited and sutimlimab, a humanized monoclonal antibody directed against complement factor C1s, may be potentially useful for inhibition of the classical complement pathway.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29737533",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Sutimlimab is a novel humanized monoclonal antibody directed against classical pathway complement factor C1s.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/32176765",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "SIONS: In patients with cold agglutinin disease who received sutimlimab, selective upstream inhibition of activity in the classic complement pathway rapidly halted hemolysis, increased hemoglobin levels, and reduced fatigue. (Fund",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33826820",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The complement C1s inhibitor sutimlimab is an emerging option in the second line and may also find its place in the first line in specific situations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33512410",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "C1s Inhibition by BIVV009 (Sutimlimab) Prevents Complement-Enhanced Activation of Autoimmune Human B Cells In Vitro.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30635392",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "In this study, we use BIVV009 (Sutimlimab), a clinical stage, humanized mAb that specifically inhibits the CP-specific serine protease C1s to evaluate the impact of upstream CP antagonism on activation and proliferation of normal and autoimmune human B cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30635392",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Novel treatment options that target the classical complement pathway are under development and appear very promising, and the C1s inhibitor sutimlimab is currently being investigated in two clinical Phase II and III trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31114413",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Of these, the anti-C1s monoclonal antibody sutimlimab has shown favorable activity in CAD, while the anti-C3 cyclic peptide pegcetacoplan appears to be promising in PNH as well as CAD, and may also have a therapeutic potential in wAIHA.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31523413",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "t pathway. Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33826820",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "ent options that target the classical complement pathway are under development and appear very promising, and the C1s inhibitor sutimlimab is currently being investigated in two clinical Phase II and III trials. These achie",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31114413",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "apeutic options for these complement-mediated disorders are limited and sutimlimab, a humanized monoclonal antibody directed against complement factor C1s, may be potentially useful for inhibition of the classical complement pathway. A ph",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29737533",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "is trial tested the hypothesis that the anti-C1s antibody sutimlimab would ameliorate hemolytic anemia. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30559259",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "s study, we use BIVV009 (Sutimlimab), a clinical stage, humanized mAb that specifically inhibits the CP-specific serine protease C1s to evaluate the impact of upstream CP antagonism on activation and proliferation of normal and autoimmune human B cells. We repor",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30635392",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this phase 1 trial, we evaluated the safety and activity of BIVV009 (sutimlimab, previously TNT009), a targeted C1s inhibitor, in 10 subjects with active or past bullous pemphigoid (NCT02502903).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31229501",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": " and activity of BIVV009 (sutimlimab, previously TNT009), a targeted C1s inhibitor, in 10 subjects with active or past bullous pemphigoid (NCT02502903",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31229501",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "and sutimlimab, a humanized monoclonal antibody directed against complement factor C1s, may be potentially useful for inhibition of the classical comp",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29737533",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ". Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathw",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33826820",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": ". This trial tested the hypothesis that the anti-C1s antibody sutimlimab would ameliorate hemolytic anemia. Ten patients with cold agglutinin disease ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30559259",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "cted therapies (ibrutinib, venetoclax, parsaclisib) and inhibitors of complement (sutimlimab, pegcetacoplan), spleen tyrosine kinases (fostamatinib), ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33261023",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "nt pathway. Sutimlimab, a humanized monoclonal antibody, selectively targets the C1s protein, a C1 complex serine protease responsible for activating this pathway.METHODS: We conducted a 26-week multicenter, open-label, single-group study to assess the efficacy and safety of intravenous sutimlimab in patients with cold agglutinin disease and a recent hi",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/33826820",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This trial tested the hypothesis that the anti-C1s antibody sutimlimab would ameliorate hemolytic anemia.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30559259",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "C1s"
}